TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05144542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Participants smoke their usual brand of cigarettes for 26 weeks.
Description: Participants smoke their usual brand of cigarettes for 26 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Participants will vape electronic cigarettes for 26 weeks.
Description: Participants will vape electronic cigarettes for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Smoke usual brand of cigarettes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Vape e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day.
Study: NCT06049316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular stabilization exercises
Description: In Scapular stabilization exercise, following treatment protocol will involve.~* In supine position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree. After this patient will raise his hand overhead with 90 degree flexion and elbow extension and also perform scapular retraction. (10 sec hold, 10 reps, 20 sec break).~* In quadrupled position with 120 degree flexion and shoulder abduction patient will lifted his hands. (10 sec hold, 10 reps, 20 sec break) TYI exercises will be administered~* T shape: Place both arms horizontal with thumbs up. (10 times, 5 sec hold, 3 sets)~* Y-shape: In prone lying place arms in 45 degree. (10 times, 5 sec hold, 3 sets)~* I-shape: In prone position patients will place his both arms overhead. (10 times, 5 sec hold, 3 sets).~These above exercises will perform 3 times a week for eight weeks.
Study: NCT06462872

Intervention type: OTHER
Intervention: observational study
Description: It is an observational study
Study: NCT03640377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: Praziquantel given as crushed tablets (40 or 80 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: Praziquantel given as crushed tablets (40 or 80 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: Praziquantel given as crushed tablets (40 or 80 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: Praziquantel given as crushed tablets (40 or 80 mg/kg)
Study: NCT05873621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG-guided lymphadenectomy
Description: Excision of ICG-fluorescent lymph nodes in addition to standard laparoscopic total mesorectal excision in rectal cancer patients after neoadjuvant chemoradiation
Study: NCT05654207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeCare
Description: WeCare combines two evidence-based strategies -- universal screening using the Computerized Adaptive Screen for Suicidal Youth and an adapted version of the SAFETY-ACUTE, which incorporates PI Lindsey's extensive work with Black youth, their families, and community stakeholders to develop culturally tailored strategies for addressing treatment barriers.
Study: NCT04995926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labial mucosal epithelium grafting for corneal limbus substitution
Description: Labial mucosa epithelium grafting for corneal limbus substitution will be used to treat limbal stem cell deficiency by way of corneal surface re-epithelization
Study: NCT01084486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT05280808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental phone app used for self-fitting of hearing aids
Description: This software allows participants to set up hearing aids as appropriate for their hearing loss
Study: NCT04853537

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intermittent fasting diet
Description: intermittent fasting diet to obese pregnant women \>30 BMI and incidence of gestational diabetes
Study: NCT05496738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07264660 intravenous single ascending dose
Description: PF-07264660 will be administered intravenously in single ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07264660 subcutaneous multiple ascending dose
Description: PF-07264660 will be administered subcutaneously in multiple ascending doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous placebo
Description: Placebo will be administered intravenously in single ascending doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: subcutaneous placebo
Description: Placebo will be administered subcutaneously in multiple ascending doses
Study: NCT06049316

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapular functional exercises
Description: In Scapular functional exercises, following treatment protocol will involve~* Press-up (in a chair).~* Push-up plus, Grade 1, in oblique position exercise will be performed with the support of a table. After progression perform this in horizontal plane.~* Lateral pull down~* Horizontal pull apart~* Prone flexion: in prone position on plinth. Both arms placed overhead, and then raise arms towards ceiling.~* Prone rows: in prone position, with elbow straight, slowly raise arms towards ceiling while bending the elbows.~These all above exercises will perform by holding dumbbells in hands (20RM at first week, 10RM at last week) with 3 sets, 3 times a week for eight weeks.
Study: NCT05028088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.
Study: NCT05515263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention snack
Description: To be eaten in replacement of usual snacks twice a day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control snack
Description: To be eaten in replacement of usual snacks twice a day for 8 weeks.
Study: NCT06209125

Intervention type: DEVICE
Group type: OTHER
Intervention: hybrid aesthetic functional appliance
Description: treatment of class II division one malocclusion
Study: NCT05937282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will receive propofol infusion in the dose of 3 mg/kg/hr. 25 ml propofol 1% (10 mg /ml) in 50 ml syringe pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr.25 ml lidocaine 1% (10 mg/ml) in 50 ml syringe pump.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients will receive infusion of 25 ml normal saline in 50ml syringe pump (control group).
Study: NCT04302259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent Spine Interface
Description: ISI-C is a bi-directional, two anatomical location Epidural Electrical Stimulation (EES) system to bridge the lesion core in patients with chronic complete and incomplete spinal cord injury (SCI). This Intelligent Spine Interface, or ISI will interpret recorded neural information from above a spinal cord lesion and transfer that information, via deep neural network-based interpreters (i.e. models), to stimulation sites (electrodes) below the lesion with the aim of restoring volitional control of the lower limb.
Study: NCT04708054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06519175

Intervention type: OTHER
Intervention: Conservative treatment
Description: Patients are provided with physiotherapy support and the provision of prostheses with the goal of ensuring as much walking functionality as possible.

Intervention type: PROCEDURE
Intervention: Single or multi-stage surgery
Description: Correction of the deformity is pursued by one or more surgical procedures with the timing and the techniques (growth modulation, acute correction, gradual correction, soft tissues procedures, combined techniques) chosen according to the surgeon's preference to achieve the maximum possible walking functionality without orthopedic aids.

Intervention type: PROCEDURE
Intervention: Amputation
Description: Limb surgery, whether or not associated with realignment or soft-tissue surgery, is performed, aimed at providing the maximum possible walking function through a prosthesis.
Study: NCT05348694

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pendulum WBF-038
Description: All bacteria contained in Pendulum WBF-038 are commensal organisms that have been repeatedly documented to inhabit the human gastrointestinal tract under normal circumstances. Pendulum's WBF-038 is a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pendulum Placebo
Description: Pendulum placebo capsules containing magnesium stearate
Study: NCT05034354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote physiological monitoring
Description: Participants will be provided with a Bluetooth capable weight scale (A\&D Medical UC-352BLE or Beurer BY90), oxygen saturation monitor (Contec Medical Systems CMS50D-BT) and automatic blood pressure monitor (A\&D Medical UA- 651BLE) to use daily for at least 10 days of a 14-day trial period. Data will be sent via the Sphygmo App to the pediatric cardiology for monitoring. Parents and healthcare providers will be asked to participate in a qualitative interview and the end of the 14-day period to provide feedback on the devices and Sphygmo™ platform.
Study: NCT04889651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9004
Description: BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9004
Description: BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9004-1
Description: BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9004-1
Description: BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
Study: NCT05948982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Mesenchymal Stem Cells
Description: The stem cell infusion route is peripheral intravenous infusion, once every 4 weeks for a total of 3 infusions. All subjects received experimental drugs and conventional treatment during the study period.
Study: NCT05648357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Tetra Vaccine
Description: A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.
Study: NCT04197505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLIR E95 camera
Description: Video will be recorded during the thermal reading for later computer analysis. The following variables will be analyzed: (1) the difference between the mean temperature between the injured and healthy extremities, (2) the difference between the maximum temperatures of both the injured and healthy extremities (ΔTmax), and (3) the difference between the area covered by each isotherm in both the injured and uninjured extremities (Δpix). FLIR software tools and MATLAB software will be used for the analysis.
Study: NCT06066515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: survodutide
Description: once weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: survodutide
Description: once weekly subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once weekly subcutaneous injection
Study: NCT05412420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Self-Reporting of Symptoms
Description: At baseline, clinical research staff will:~* verify the possibility of an internet connection at the patient's home~* help the patient to fill in the 1st questionnaire (baseline questionnaire - frailty)~Every two weeks for 3 months:~* patients complete questionnaires via app (toxicity; quality of life, medication adherence)~* responses are verified by clinical research staff~* In case of severe symptoms, the clinician contacts the patient and arranges for management.~At the end of the study :~- patients answer a satisfaction questionnaire
Study: NCT06358677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Tretinoin
Description: Topical tretinoin will be applied to one half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo (topical moisturizer) will be applied to the other half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
Study: NCT05524909

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Risk Estimate
Description: The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genetic Risk Estimate + Fitbit Functions
Description: The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate.
Study: NCT06553820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group I, Yoga 20 minutes x2 pr week
Description: App-based MediYoga exercises, 20 minutes per session, twice a week for a total of 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group II, Yoga 40 minutes x2 pr week
Description: App-based MediYoga exercises, 40 minutes per session, twice a week for a total of 10 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group, No intervention
Description: standard of care only
Study: NCT05639868

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted CPR
Description: Participants in V-CPR group get video-based (vocal and visual) instructions from the dispatcher.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-assisted CPR
Description: Participants in V-CPR group get video-based (vocal and visual) instructions from the dispatcher.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-assisted CPR
Description: Participants in T-CPR group get voice-based (vocal) instructions from the dispatcher.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone-assisted CPR
Description: Participants in T-CPR group get voice-based (vocal) instructions from the dispatcher.
Study: NCT04964232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared Camera
Description: The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Temperature Probe
Description: In patients undergoing general anesthesia, the Esophageal temeperature parameters are measured using an Esophageal probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin temperature probe
Description: In patients undergoing general anesthesia, the skin spot temeperature parameters are measured using an skin adhesive probe.
Study: NCT06064201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-chain fatty acids (SCFAs)
Description: The SCFAs mixture contains acetate, butyrate, and propionate in a ratio of 60:20:20, and the total daily amount of SCFAs is equivalent to the fermentation of 10g of arabinoxylan oligosaccharides. Participants will be asked to consume these capsules spread at four intervals throughout the day. The nursing staff will distribute the capsules to the participants individually, supervise their intake, and monitor adherence by capsule count.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To serve as a placebo, microcrystalline cellulose will be included in the same type of CDCs.
Study: NCT06666725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from three restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from three restaurant menus, displayed with labels as specified by their assigned group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from three restaurant menus, displayed with labels as specified by their assigned group
Study: NCT06673810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle Weighted Cuffs Training Along with Routine Physical Therapy Exercises
Description: Group A will have free ankle weighted cuffs while performing routine physical therapy. These weighted cuffs will be above of the child's ankle and child will be encouraged to perform his/her routine physical activities. Ankle weights will correspond to 2% to 3% of the individual's body weight (sandbags) will be attached at 5 cm above the left and right ankle joints

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Physical Therapy Exercises
Description: Group B will perform all the routine physical exercises which include jogging, walk/run interval training, treadmill training and cycling . Intervention period will be of 6 weeks comprising of 3 sessions per week of 30 to 45 minutes per session
Study: NCT06598943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrekibart
Description: Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrekibart
Description: Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered